Discover fascinating facts about Ethiopia and explore its rich history unique culture diverse landscapes traditions and remarkable heritage while learning more about what makes this country so ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...

The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...

Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...

An explosion at Qatar’s main liquefied natural gas (LNG) processing facility has killed 13 people and injured dozens. Qatar’s Energy Minister, Saad al-Kaabi, said on Monday that the blast at the Ras ...

The Higher Education Commission (HEC) in Pakistan has said universities should stop running their own MS, MPhil and PhD entry tests and move admissions to GRE/HAT (Graduate Record Examination/Higher ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

RAS mutations are among the most common drivers in cancer, particularly in pancreatic, colorectal, and lung tumors. Despite that, directly targeting RAS proteins proved extremely difficult for years, ...